Journal
PLACENTA
Volume 121, Issue -, Pages 79-81Publisher
W B SAUNDERS CO LTD
DOI: 10.1016/j.placenta.2022.03.003
Keywords
SARS-CoV-2; COVID; Pregnancy; Placentitis; Stillbirth; Viremia
Funding
- Friends of Prentice
- Stanley Manne Children's Research Institute
- National Center for Advancing Translational Sciences [UL1TR001422]
- Na-tional Institute of Biomedical Imaging and Bioengineering [K08EB030120]
- National Institute of Allergy and Infectious Diseases [K23AI139337]
- NIH-supported Third Coast CFAR [P30 AI117943]
- NIH [U19 AI135964]
- Walder Foundation's Chicago Coronavirus Assessment Network (Chicago CAN) Initiative
Ask authors/readers for more resources
The presence of maternal viremia may be a possible marker of COVID placentitis, as shown in a study investigating SARS-CoV-2 infection during pregnancy. The study found that two cases of placentitis with viremia resulted in one stillbirth and one healthy infant.
SARS-CoV-2 infection in pregnancy and COVID placentitis are associated with an increased risk of stillbirth. We sought to investigate the presence of maternal viremia in people with SARS-CoV-2 infection during pregnancy who had histologic placentitis versus those without placentitis. SARS-CoV-2 qRT-PCR was performed on plasma from 6 patients with COVID placentitis and 12 matched controls without placentitis. SARS-CoV-2 infection occurred between 4/2020-1/2021; the latency between SARS-CoV-2 diagnosis and delivery was 0-76 days. Two placentitis cases demonstrated viremia (1 stillbirth and 1 well infant), while 12/12 controls were negative. Future research may consider viremia as a possible marker of COVID placentitis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
